First‐in‐human development of a pharmacodynamic biomarker for PAC1 receptor antagonists using intradermal injections of maxadilan

• Päätekijät: Heleen Marynissen (Tekijä), Linde Buntinx (Tekijä), Dorien Bamps (Tekijä), Marleen Depre (Tekijä), Els Ampe (Tekijä), Anne Van Hecken (Tekijä), Kristin Gabriel (Tekijä), Steve Sands (Tekijä), Gabriel Vargas (Tekijä), Jan de Hoon (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2022-08-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Maxadilan, a potent vasodilator peptide, selectively activates the PAC1 receptor, a promising target for migraine therapy. Therefore, maxadilan has been suggested as a tool to study the pharmacodynamics (PDs) of PAC1 receptor antagonists. The objectives of this first‐in‐human study were to:...